FDA endorses experimental Alzheimer's drug for full FDA approval | NewsNation Live

The drug, Leqembi, received conditional approval from the FDA in January based on early results suggesting it could slow Alzheimer’s progression by several months. The FDA now is reviewing more definitive results to decide whether the drug should receive the agency’s full endorsement. Dr. Corey Hebert discusses the pros and cons of this medication being FDA-approved and widely used. #FDA #Alzheimers #Legembi Get a fast-paced look at the latest from the border to Main Street to the White House on "NewsNation Live with Marni Hughes." Weekdays starting at 10a/9C.#NewsNationLive NewsNation is your source for fact-based, unbiased news for all America. More from NewsNation: https://www.newsnationnow.com/ Get our app: https://trib.al/TBXgYpp Find us on cable: https://trib.al/YDOpGyG How to watch on TV or streaming: https://trib.al/Vu0Ikij